Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Gains from Investment Securities (2019 - 2022)

C4 Therapeutics (CCCC) has 4 years of Gains from Investment Securities data on record, last reported at $44.1 million in Q1 2022.

  • For Q1 2022, Gains from Investment Securities rose 156299.06% year-over-year to $44.1 million; the TTM value through Dec 2022 reached $44.1 million, changed N/A, while the annual FY2022 figure was $44.1 million, 636.48% up from the prior year.
  • Gains from Investment Securities reached $44.1 million in Q1 2022 per CCCC's latest filing, up from $20.1 million in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $44.1 million in Q1 2022 and bottomed at $28176.0 in Q1 2021.
  • Average Gains from Investment Securities over 4 years is $11.0 million, with a median of $2.5 million recorded in 2020.
  • Peak YoY movement for Gains from Investment Securities: increased 7.01% in 2020, then skyrocketed 156299.06% in 2022.
  • A 4-year view of Gains from Investment Securities shows it stood at $2.4 million in 2019, then increased by 7.01% to $2.5 million in 2020, then surged by 694.12% to $20.1 million in 2021, then surged by 118.9% to $44.1 million in 2022.
  • Per Business Quant database, its latest 3 readings for Gains from Investment Securities were $44.1 million in Q1 2022, $20.1 million in Q4 2021, and $1.6 million in Q3 2021.